http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109010811-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-12 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-13 |
| filingDate | 2018-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109010811-B |
| titleOfInvention | Immune preparation of broad-spectrum anti-tumor mouse model by using apoptotic body vaccine |
| abstract | The invention protects a broad-spectrum anti-tumor mouse model prepared by the apoptosis corpuscle vaccine immunization, and the mouse is prepared by the apoptosis corpuscle vaccine immunization and has broad-spectrum anti-tumor property. The establishment method comprises the following steps: inducing cancer cell apoptosis in vitro by nutritional deficiency method to obtain apoptotic body. Kunming mice were immunized with apoptotic bodies once a week by subcutaneous injection of 25mg/kg apoptotic bodies per mouse for a total of five weeks. The results of in vivo antitumor experiments on mice show that the tumor inhibition rate of H22 tumor-bearing mice can reach 80.27 percent, and the molding success rate reaches 50 percent. The invention aims at the phenomena that in the existing immune anti-tumor animal experiment, the positive control modeling is unreasonable, and no broad-spectrum immune anti-tumor mouse exists in the market at present. The mouse immunized by the apoptotic bodies solves the problem, has stronger anti-tumor immunity, and has stable model and high production quality. |
| priorityDate | 2018-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.